1 trials follow rigid protocols, with pre-set dose escalation and fixed cohorts. But modern drug development increasingly demands adaptive designs—flexible approaches that allow protocol changes based on real-time data without compromising participant safety or trial integrity. Adaptive designs in Phase 1 can accelerate decision-making, optimize dose selection, and reduce unnecessary exposure, especially in high-risk, complex, or innovative therapeutic programs. This article explores the concepts, benefits, risks, and implementation strategies of adaptive designs in early-phase trials.

What Is an Adaptive Design?

An adaptive design allows pre-planned modifications to the trial based on interim data analyses. These changes are governed by statistical control and operational rigor. Adaptive features are incorporated in the protocol and reviewed by regulatory bodies before trial initiation.

Why Use Adaptive Designs in Phase 1?

• Improved safety: Escalation only occurs after real-time safety and PK review
• Faster decision-making: Allows dose skipping or expansion if justified
• Resource efficiency: Minimizes subject exposure to subtherapeutic or toxic doses
• Supports complex molecules: Ideal for biologics, gene therapies, and targeted drugs

Types of Adaptations in Phase 1 Trials

1. Dose Escalation Adaptations

• Change dose levels or skip doses based on emerging safety/PK data
• Example: Move from 10 mg to 40 mg if 20 mg predicted exposure overlaps with 10 mg

2. Cohort Expansion

• Add more subjects to a well-tolerated dose level for additional safety or PD data
• Common in oncology and rare diseases

3. Schedule Modifications

• Shift from single dose to multiple dose arms
• Change frequency (e.g., weekly to bi-weekly) if exposure exceeds expectations

4. Route of Administration

• Adapt based on feasibility (e.g., IV to SC transition)

5. Cohort Substitution or Expansion Based on Biomarkers

• Use interim PD or biomarker data to select more targeted subgroups

Common Adaptive Designs in Phase 1

1. Bayesian Logistic Regression Model (BLRM)

• Probabilistic model to assess the dose-toxicity relationship
• Guides dose escalation using prior and emerging data

2. Continual Reassessment Method (CRM)

• Statistical model estimates maximum tolerated dose (MTD) continuously
• Reduces the number of patients exposed to ineffective or toxic doses

3. Modified Toxicity Probability Interval (mTPI)

• Uses toxicity intervals to guide decisions on escalation, de-escalation, or expansion
• Intuitive and easier to implement than Bayesian methods

4. Seamless Phase 1/2 Designs

• Combine dose-finding and early efficacy in a single protocol
• Transition from dose escalation to cohort expansion based on emerging data

Regulatory Expectations

FDA

• Supports adaptive designs if scientifically justified and pre-specified
• Requests clear statistical methodology, simulation results, and stopping rules
• Pre-IND meetings advised to align expectations

EMA

• Allows flexibility but expects risk mitigation plans for high-dose transitions
• Must define operational criteria and documentation procedures

CDSCO

• Permits protocol amendments with scientific justification
• Adaptations must be ethics committee approved before implementation

Operational Considerations

1. Real-Time Data Access

• Ensure EDC systems, PK labs, and clinical teams can deliver clean data quickly

2. Safety Review Committees

• Mandatory for interim decision-making (e.g., dose escalation, halting)

3. Protocol and Statistical Planning

• Define adaptation types, boundaries, and decision criteria in advance
• Simulate possible trial paths for regulatory review

4. Documentation and Governance

• Track all adaptations with clear rationale and decision logs
• Update trial registry and ethical board documentation

Examples from Industry

Example 1: Oncology Biologic Using BLRM

• FIH trial used Bayesian modeling to determine RP2D in only 28 patients
• Allowed 3 dose skips and included a biomarker-enriched expansion cohort

Example 2: RNA Therapy with Weekly to Monthly Transition

• Initial Phase 1 evaluated weekly injections, then transitioned to monthly based on long half-life
• Adaptation approved via protocol amendment after SRC review

Example 3: Seamless Phase 1/2 in Rare Disease

• Dose escalation followed by cohort expansion in mutation-positive patients
• Enabled submission of Breakthrough Designation based on early efficacy

Best Practices

• Engage with regulatory authorities early to align on design
• Use simulation tools to justify adaptation decisions
• Maintain transparent and real-time communication with internal and external stakeholders
• Ensure all adaptation rules are documented in the protocol or SAP
• Integrate adaptive features into EDC, IWRS, and DSMB workflows